Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics

por Gerard, Emma, Zohar, Sarah, Thai, Hoai‐Thu, Lorenzato, Christelle, Riviere, Marie‐Karelle, Ursino, Moreno
Publicado 2021

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone

por Thai, Hoai‐Thu, Gaudel, Nadia, Cerou, Marc, Ayral, Geraldine, Fau, Jean‐Baptiste, Sebastien, Bernard, van de Velde, Helgi, Semiond, Dorothée, Veyrat‐Follet, Christine
Publicado 2021

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma

por Koiwai, Kimiko, El‐Cheikh, Raouf, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean‐Baptiste, Veyrat‐Follet, Christine, Risse, Marie‐Laure, van de Velde, Helgi, Semiond, Dorothée, Nguyen, Laurent
Publicado 2021

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myelom...

por Rachedi, Fatiha, Koiwai, Kimiko, Gaudel‐Dedieu, Nadia, Sebastien, Bernard, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean Baptiste, Nguyen, Laurent, van de Velde, Helgi, Veyrat‐Follet, Christine, Semiond, Dorothée
Publicado 2022